What happened with NBIX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Neurocrine Biosciences’ main medicine, INGREZZA, treats tardive dyskinesia and chorea associated with Huntington’s disease. It accounts for most of the company’s revenue. The company also sells CRENESSITY for classic congenital adrenal hyperplasia, an endocrine disorder. CRENESSITY is approved as an add-on to glucocorticoid replacement treatment, not a replacement for it. Beyond these marketed medicines, Neurocrine researches and develops treatments for neurological, psychiatric, endocrine and immunological disorders.
Specialty pharmacies and distributors buy its medicines for delivery to patients. INGREZZA reaches the U.S. market through a limited specialty network, while CRENESSITY uses a sole specialty pharmacy. A small group of these customers accounts for nearly all product sales. Insurance coverage and reimbursement help support patient access, and most current revenue comes from federal healthcare programs, including Medicare and Medicaid. The business therefore depends heavily on continued prescribing and those programs’ payment policies, including required discounts and rebates.
Neurocrine has no manufacturing facilities of its own. Contract manufacturers produce its medicines, and outside logistics providers package, store and ship them, making reliable supply dependent on these providers and their compliance with drug-manufacturing standards.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Teva’s AUSTEDO and AUSTEDO XR compete for adults with tardive dyskinesia and patients with Huntington’s-related chorea against INGREZZA, the medicine that generates most of Neurocrine Biosciences’ product sales. Watch uptake of these Teva medicines in those patient groups for signs of pressure on INGREZZA.
Xenon Pharmaceuticals licenses sodium-channel drug programs to Neurocrine Biosciences in return for milestone payments and potential royalties, while its own depression treatments could compete with Neurocrine’s pipeline. Xenon’s entire $7.5 million revenue in 2025 came from a Neurocrine collaboration milestone, not medicine sales.
Takeda licensed osavampator to Neurocrine Biosciences outside Japan and kept Japan rights, giving both companies a financial interest in the drug’s success. Neurocrine funds development outside Japan and may pay Takeda milestones and sales royalties; Takeda funds Japan development, where sales could generate royalties for Neurocrine.
Neurocrine Biosciences relies on Voyager Therapeutics for technology and development work that deliver gene therapies to the nervous system, and covers agreed preclinical costs with one shared-cost exception. Watch the first GBA1 clinical trial’s topline results: they could let Voyager opt to share U.S. development, commercialization, costs and profits for the Parkinson’s program.
MapLight Therapeutics’ experimental M1/M4 muscarinic schizophrenia treatment competes in development with Neurocrine Biosciences’ direclidine, NBI-570 and NBI-567; MapLight has no medicine sales yet. Its Phase 2 ZEPHYR results, which it expected in the third quarter of 2026, are the concrete readout to watch on this competing treatment approach.
AbbVie makes and sells Neurocrine Biosciences’ licensed elagolix medicines, ORILISSA and ORIAHNN, and pays Neurocrine royalties on sales. Watch those medicines’ sales for endometriosis and uterine fibroids, rather than AbbVie’s overall results, for the direct effect on Neurocrine’s collaboration revenue.
Fed Interest Rate Decision
Neurocrine’s cash and marketable securities help fund operations, so Fed rate decisions matter because they affect investment income and the value of its debt securities.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could increase income as Neurocrine reinvests cash and securities, but may also lower the value of its debt securities.
If it comes in below expectations
Lower rates could reduce income as Neurocrine reinvests cash and securities, but may also support the value of its debt securities.
ABBVIE INC. earningsABBV
AbbVie’s report will show whether sales of ORILISSA and ORIAHNN are supporting the royalties Neurocrine Biosciences receives.
Focus on AbbVie’s ORILISSA and ORIAHNN sales for endometriosis and uterine fibroids, not just AbbVie’s overall results. Growth in those medicines gives Neurocrine more sales to earn royalties on; weaker sales mean less support for this source of collaboration revenue.
Neurocrine Biosciences Inc earningsThis company
Neurocrine Biosciences’ report will show whether INGREZZA demand can withstand lower net pricing and CRENESSITY can add meaningfully to sales.
Read INGREZZA prescription demand alongside its net price—the price after discounts and rebates—and CRENESSITY sales. If INGREZZA demand holds up against net-price pressure while CRENESSITY adds sales, both medicines are contributing; if pricing weighs on INGREZZA and CRENESSITY adds little, the business still relies mainly on INGREZZA.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report will show whether AUSTEDO and AUSTEDO XR are gaining use among the same patient groups as INGREZZA.
Compare reported use of Teva’s AUSTEDO and AUSTEDO XR with INGREZZA’s position in tardive dyskinesia and Huntington’s-related chorea. Faster growth for Teva’s medicines would mean more pressure on INGREZZA; weak growth would mean less direct pressure, but would not prove patients switched to INGREZZA.
Voyager Therapeutics, Inc. earningsVYGR
Voyager Therapeutics’ report and any GBA1 trial results it discloses will show whether it may opt to share U.S. development and commercialization of Neurocrine’s Parkinson’s program.
Watch the GBA1 trial results and whether Voyager chooses to share U.S. development and commercialization. If the results support the program and Voyager opts in, Neurocrine will share costs and future profits under the agreement; if results disappoint or Voyager does not opt in, that cost- and profit-sharing arrangement is not part of the program’s economics.
